| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1600-6143.2010.03156.X |
| P698 | PubMed publication ID | 20642678 |
| P50 | author | Giuseppe Remuzzi | Q16561003 |
| P2093 | author name string | M. Noris | |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | kidney transplantation | Q740909 |
| P304 | page(s) | 1517-1523 | |
| P577 | publication date | 2010-06-25 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | Thrombotic Microangiopathy After Kidney Transplantation | |
| P478 | volume | 10 |
| Q33395562 | A case of progressive thrombotic microangiopathy after ABO-incompatible renal transplantation |
| Q33422224 | A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience |
| Q33410321 | A newly identified mutation in the complement factor I gene not associated with early post-transplant recurrence of atypical hemolytic-uremic syndrome: a case report |
| Q33418553 | A non-invasive laboratory panel as a diagnostic and prognostic biomarker for thrombotic microangiopathy: development and application in a Chinese cohort study |
| Q41043453 | Acute Kidney Injury in Pregnancy-specific Disorders |
| Q26796453 | Advances and challenges in the management of complement-mediated thrombotic microangiopathies |
| Q33835780 | American Society of Nephrology Quiz and Questionnaire 2013: transplantation |
| Q33414342 | An analysis of transplant glomerulopathy and thrombotic microangiopathy in kidney transplant biopsies |
| Q36495141 | Annexin A2 Enhances Complement Activation by Inhibiting Factor H |
| Q36922103 | Antibody-Mediated Rejection in Sensitized Nonhuman Primates: Modeling Human Biology. |
| Q21202864 | Atypical hemolytic uremic syndrome |
| Q33400211 | Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics |
| Q27023137 | Atypical hemolytic uremic syndrome: from diagnosis to treatment |
| Q38510972 | Banff 2013 update: Pearls and pitfalls in transplant renal pathology |
| Q33411363 | Blood disorders after kidney transplantation |
| Q33421793 | Blood disorders typically associated with renal transplantation |
| Q36641955 | Characteristics and Outcomes of Renal Transplant Recipients with Hemolytic Uremic Syndrome in the United States |
| Q38076666 | Clinical and histological predictors of long-term kidney graft survival. |
| Q92553772 | Clinical and pathological features of thrombotic microangiopathy influencing long-term kidney transplant outcomes |
| Q33412327 | Clinical aspects: focusing on key unique organ-specific issues of renal transplantation |
| Q48018119 | Clinical dissection of thrombotic microangiopathy |
| Q37974480 | Clinical role of the renal transplant biopsy |
| Q33406025 | Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype |
| Q33396528 | Complement activation during liver transplantation-special emphasis on patients with atypical hemolytic uremic syndrome |
| Q26829790 | Complement cascade and kidney transplantation: The rediscovery of an ancient enemy |
| Q33405522 | Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome |
| Q39371134 | Complement in Kidney Transplantation |
| Q35567841 | Complement involvement in kidney diseases: From physiopathology to therapeutical targeting |
| Q37522557 | Complement related kidney diseases: Recurrence after transplantation |
| Q58727886 | Complement-mediated thrombotic microangiopathy associated with lupus nephritis |
| Q92627201 | Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome |
| Q33394542 | Controlling coagulation dysregulation in xenotransplantation |
| Q38843499 | Current status of pediatric renal transplant pathology |
| Q30403833 | De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients |
| Q40861312 | De novo post-transplant thrombotic microangiopathy localized only to the graft in autosomal dominant polycystic kidney disease with thrombophilia |
| Q33419720 | De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus |
| Q47440056 | De novo thrombotic microangiopathy after kidney transplantation |
| Q33403602 | De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival |
| Q33395998 | Do NK cells contribute to the pathophysiology of transplant-associated thrombotic microangiopathy? |
| Q52624119 | Early Conversion from Tacrolimus to Belatacept in a Highly Sensitized Renal Allograft Recipient with Calcineurin Inhibitor-Induced de novo Post-Transplant Hemolytic Uremic Syndrome. |
| Q33438587 | Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report |
| Q33395870 | Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation--a case report |
| Q62588865 | Effect of Thrombophilic Factors on Renal Graft Function: A Single-Center Experience |
| Q35668667 | Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient |
| Q33438583 | Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report |
| Q33404656 | End-stage kidney disease due to haemolytic uraemic syndrome--outcomes in 241 consecutive ANZDATA registry cases |
| Q47386658 | Fibrin thrombi in deceased donor kidneys: Prevalence and influence on graft function and graft survival in transplanted patients. |
| Q33441069 | HUS and atypical HUS. |
| Q90618941 | Haemolytic uremic syndrome: diagnosis and management |
| Q57190615 | Hypertension guidelines: How do they apply to kidney transplant recipients |
| Q90599762 | Isolated thrombotic microangiopathy of the small intestine in a patient with atypical hemolytic uremic syndrome - a case report |
| Q90225649 | Low efficacy of vaccination against serogroup B meningococci in patients with atypical hemolytic uremic syndrome |
| Q57161996 | Management of hemolytic uremic syndrome |
| Q90641306 | Metastatic lung adenocarcinoma- associated thrombotic microangiopathy in a renal transplant recipient |
| Q39968188 | Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field |
| Q51353137 | Postpartum aHUS secondary to a genetic abnormality in factor H acquired through liver transplantation. |
| Q33423305 | Posttransplant outcome of atypical haemolytic uraemic syndrome in a patient with thrombomodulin mutation: a case without recurrence |
| Q30544649 | Pros and cons for C4d as a biomarker |
| Q40075347 | Rare genetic variants in Shiga toxin-associated haemolytic uraemic syndrome: genetic analysis prior to transplantation is essential |
| Q38129623 | Recurrence of glomerulonephritis after renal transplantation. |
| Q33407913 | Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy |
| Q33411571 | Renal function in normal and disordered pregnancy |
| Q59507180 | Serum biomarkers in uncontrolled no heart-beating donors may identify kidneys that will never work after transplantation |
| Q33409586 | Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients |
| Q90419326 | Survey of thrombotic microangiopathy within 1 week after kidney transplantation between 2010 and 2015 in Japan |
| Q36554196 | Tacrolimus associated localized thrombotic microangiopathy developing in early stage after renal transplantation |
| Q33432099 | The alternative pathway of complement and the thrombotic microangiopathies |
| Q33426548 | The inferior impact of antibody-mediated rejection on the clinical outcome of kidney allografts that develop de novo thrombotic microangiopathy. |
| Q38151921 | The specificity of acute and chronic microvascular alterations in renal allografts |
| Q48207019 | Thrombalexin: Use of a Cytotopic Anticoagulant to Reduce Thrombotic Microangiopathy in a Highly Sensitized Model of Kidney Transplantation |
| Q33425766 | Thrombotic Microangiopathy as a Cause of Chronic Kidney Transplant Dysfunction: Case Report Demonstrating Successful Treatment with Eculizumab |
| Q90451497 | Thrombotic Microangiopathy in a Transplant Recipient |
| Q33443111 | Thrombotic Thrombocytopenic Purpura: Pathogenesis, Diagnosis, and Potential Novel Therapeutics |
| Q33398129 | Thrombotic microangiopathy after living-donor liver transplantation |
| Q58754943 | Thrombotic microangiopathy after renal transplantation: Current insights in and recurrent disease |
| Q33402372 | Thrombotic microangiopathy and associated renal disorders |
| Q52650422 | Thrombotic microangiopathy associated with Mycoplasma pneumoniae infection. |
| Q33430684 | Thrombotic microangiopathy caused by oral contraceptives in a kidney transplant recipient |
| Q37589777 | Thrombotic microangiopathy in renal allografts |
| Q50063069 | Transplant glomerulopathy |
| Q33430681 | Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab |
| Q33408171 | Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations |
| Q33411321 | Use of belatacept as alternative immunosuppression in three renal transplant patients with de novo drug-induced thrombotic microangiopathy |
| Q38176753 | Utility of renal biopsy in the clinical management of renal disease |
Search more.